Medicare Advantage insurers denied millions of prior authorization requests in 2024, but a denial count alone cannot tell whether a particular patient was treated fairly. The important questions are what was requested, why coverage was refused, whether the decision was appealed, and what happened afterward. Public statistics identify patterns; clinical records test individual decisions.
What do the national numbers show?
KFF’s January 2026 analysis of federal data found nearly 53 million Medicare Advantage prior authorization determinations in 2024. Insurers denied about 4.1 million, or 7.7%, in whole or in part. These are authorization requests, not necessarily unique patients. One patient may need approval for several services, and a denied request does not automatically mean care was never provided.
Only 11.5% of denied requests were appealed. Among appealed denials, 80.7% were overturned. The high reversal rate deserves scrutiny, but it does not mean 80.7% of all initial denials were improper: the appealed cases are a selected subset, and some approvals follow submission of additional records. It does demonstrate why an initial denial should not automatically end the process.
What the statistics cannot prove
Insurers’ authorization rates depend partly on which services require approval, the clinical needs of enrollees, and how requests are recorded. A parent insurance company may operate several Medicare Advantage contracts, and its individual plans may have different rules. An insurer-wide rate cannot establish the correctness of a particular plan’s decision.
A meaningful investigation identifies the plan contract, requested service, clinical criteria, denial rationale, records submitted, appeal outcome, and actual treatment delay. Comparing unlike service categories can mislead. Researchers should also distinguish an initial request denied for missing information from a determination that a complete request failed medical-necessity criteria.
How to examine an individual denial
Patients should request the written determination, service codes, specific clinical criterion, and any explanation of missing records. Providers should compare the decision with the clinician’s order, examination findings, diagnostic tests, treatment history, and plan criteria effective on the decision date.
Build a dated record of submission, confirmation, information requests, initial decision, peer-to-peer discussion, appeal, and revised determination. Record whether treatment occurred and when. Do not label a medical complication as caused by the insurer without competent evidence. An accurate chronology is more useful than a broad accusation.
What changed under federal rules in 2026?
CMS’s 2024 interoperability and prior authorization final rule established, beginning in 2026, seven-calendar-day limits for standard medical-service authorization decisions and 72-hour limits for expedited decisions for certain impacted payers, including Medicare Advantage organizations. Decisions must be sooner when medical circumstances require it. The rules exclude drugs and do not impose the same new timeline on every commercial plan.
CMS also requires impacted payers to provide specific reasons for prior authorization denials. Do not apply these 2026 provisions retroactively to 2024 cases. For current requests, verify the precise coverage program and service before asserting a legal deadline.
A practical investigation checklist
Identify the plan and requested service; obtain the dated determination and actual criteria; preserve submission receipts; compare clinical documentation with the stated reason; verify the appeal route and deadline; and record the ultimate outcome. Keep patient-facing explanations separate from internal coding shorthand.
A useful appeal opening is: ‘The plan denied [service] on [date] because [reason]. Enclosed records address that criterion by documenting [facts]. Please identify any remaining requirement that is not met and provide a written reconsideration.’ The treating clinician should review clinical assertions before submission.
Frequently asked questions
Does an 80.7% reversal rate mean most denials are illegal? No. It measures reversals among appealed denials, not all denials, and says nothing definitive about the legal merits of an individual decision.
Can a provider appeal? Often, with the appropriate authorization and plan-specific procedures. For help preparing a focused appeal, see our evidence-based appeals guide.
Sources and further reading
KFF: Medicare Advantage prior authorization data
Leave a Reply